<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586012</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15010061</org_study_id>
    <nct_id>NCT02586012</nct_id>
  </id_info>
  <brief_title>Weight-based Dosing in Hemophilia A</brief_title>
  <official_title>Weight-based Dosing in Hemophilia A: A Randomized, Controlled, Open-label, Crossover Trial to Measure Factor VIII Recovery Following Factor VIII Concentrate Dosing Based on Total Body Weight, Ideal Body Weight, and Lean Body Mass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig Seaman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemophilia A is an inherited (genetic) disease where a protein, factor VIII (FVIII), which
      promotes blood clotting is missing or does not work properly. Individuals with hemophilia A
      are at risk for bleeding. Bleeding is prevented and/or treated with recombinant factor VIII
      (rFVIII), which is an FDA-approved treatment for Hemophilia A. Obesity is common among
      patients with hemophilia. Some studies have shown that obese hemophilia patients may be able
      to prevent bleeding with a lower dose of clotting factor than the dose they are currently
      receiving. The lower dose is calculated based on what a patient should weigh rather than what
      he does weigh. This is a clinical research study to test whether calculating rFVIII dosing
      based on lean body mass and ideal body weight (what a person should weigh based on his
      height) in overweight and obese patients with hemophilia is more accurate than calculating
      rFVIII dosing based on what a person actually weighs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a single center, randomized, controlled, open-label, crossover
      trial to determine if recombinant factor VIII (rFVIII) dosed according to lean body mass
      (LBM) and ideal body weight (IBW) achieves a targeted FVIII recovery with better precision
      than based on total body weight (TBW). The investigators hypothesize the use of LBM and IBW
      to determine the dose of rFVIII necessary to attain a desired FVIII recovery of 2 +/- 0.2
      IU/dl per IU/kg (100 +/- 10%) in overweight and obese (body mass index greater than or equal
      to 25 mg/m2), adult males (age 18 or older) with hemophilia A (FVIII activity 40% or less)
      will result in a 50% greater proportion of subjects within this range when compared to TBW.
      Eligible patients receiving care at the Hemophilia Center of Western Pennsylvania (HCWP) will
      be enrolled during clinic visits. Following enrollment and completion of screening
      assessment, subjects will present to HCWP for three study visits with each study visit
      occurring on successive weeks. Subjects will not have received any rFVIII for a period of at
      least 72 hours prior to each study visit. Recombinant FVIII infusion based on TBW, LBM, or
      IBW will take place during each study visit, and the order will be determined by
      randomization. During each study visit, FVIII levels will be assessed by obtaining blood
      samples before and at 10 and 30 minutes and 1 hour after infusion. Outcomes include the
      proportion of subjects achieving a desired peak FVIII recovery value of 2 +/- 0.2 IU/dl per
      IU/kg (100 +/- 10%) at 10 minutes following infusion of rFVIII dosed according to LBM and
      TBW, IBW and TBW, and LBM and IBW. The investigators will use mixed effects logistic
      regression to investigate the effect of using different weight-based dosing methods on
      attaining target FVIII levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects dosed based on LBM (Lean Body Mass) and TBW (Total Body Weight) achieving desired peak FVIII recovery.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Desired peak FVIII recovery value of 2 +/- 0.2 IU/dl per IU/kg (100 +/- 10%) at 10 minutes following infusion based on LBM and TBW. FVIII recovery values will be calculated as follows: [(weight in kg x observed FVIII recovery in IU/dL)/(dose in IU)] and expressed as IU/dL per IU/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects dosed based on IBW (Ideal Body Weight) and TBW (Total Body Weight) achieving desired peak FVIII recovery.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Desired peak FVIII recovery value of 2 +/- 0.2 IU/dl per IU/kg (100 +/- 10%) at 10 minutes following infusion based on IBW and TBW. FVIII recovery values will be calculated as follows: [(weight in kg x observed FVIII recovery in IU/dL)/(dose in IU)] and expressed as IU/dL per IU/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects dosed based on LBM (Lean Body Mass) and IBW (Ideal Body Weight) achieving desired peak FVIII recovery.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Desired peak FVIII recovery value of 2 +/- 0.2 IU/dl per IU/kg (100 +/- 10%) at 10 minutes following infusion based on LBM and IBW. FVIII recovery values will be calculated as follows: [(weight in kg x observed FVIII recovery in IU/dL)/(dose in IU)] and expressed as IU/dL per IU/kg.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>TBW, LBM, IBW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBM, IBW, TBW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBW, TBW, LBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBW, IBW, LBM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBM, TBW, IBW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBW, LBM, TBW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFVIII</intervention_name>
    <description>Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: [(weight in kg x desired FVIII increase of 100 IU/dL)/(2)].</description>
    <arm_group_label>TBW, LBM, IBW</arm_group_label>
    <arm_group_label>LBM, IBW, TBW</arm_group_label>
    <arm_group_label>IBW, TBW, LBM</arm_group_label>
    <arm_group_label>TBW, IBW, LBM</arm_group_label>
    <arm_group_label>LBM, TBW, IBW</arm_group_label>
    <arm_group_label>IBW, LBM, TBW</arm_group_label>
    <other_name>eloctate, advate, helixate, kogenate, recombinante</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males age 18 or older.

          2. Hemophilia A (FVIII activity 40% or less).

          3. Overweight or obesity defined as a BMI of 25.0-29.9 and â‰¥ 30 mg/m2, respectively.

        Exclusion Criteria:

          1. Prior history of, or currently detectable, FVIII inhibitor defined as greater than or
             equal to 0.6 Bethesda Units (BU); however, a subject with a past low-level
             non-responding inhibitor defined as less than 5 BU, with no increase in titer
             following FVIII exposure, and not detectable within 12 months of the study, despite
             FVIII exposure during that period, will be allowed to enroll on study.

          2. Allergy to FVIII products.

          3. Current rFVIII requirements do not include at least a 72-hour period without rFVIII
             administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Seaman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Seaman, MD, MS</last_name>
    <phone>412-209-7280</phone>
    <email>seamanc@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hemophilia Center of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig D Seaman, MD</last_name>
      <phone>412-209-7280</phone>
      <email>seamanc@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Craig Seaman</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

